[Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases].
Majority of patients with prostate cancer develop bone metastases which lead to serious skeletal complications. Prostate cancer guidelines recommend the use of bisphosphonates for men with bone metastases. The objective of this study was to determine the best treatment options for prostate cancer with bone metastases. Patients with clinically confirmed bone metastases were identified and the efficacy of bisphosphonates of second generation was studied. Findings from this study show that pamidronate in dose 90 mg is effective in treatment of different stages of bone metastases. All above mentioned confirms implementation of bisphosphonates of II generation into clinical practice in palliation of prostate cancer patients with bone metastases along with other treatments.